Table 3.
Treatment characteristics of 277 treated tenosynovial giant cell tumor (TGCT) patients.
| Treatment | Localized-TGCTa (n=67) | Diffuse TGCT (n=210) | |
| Initial surgery, n (%) | |||
| Arthroscopic synovectomy | 38 (57) | 113 (53.8) | |
| Open synovectomy (one- or two-staged) | 26 (39) | 90 (42.9) | |
| Combined arthroscopic/open synovectomy | 3 (4) | 0 (0.0) | |
| Total joint replacement/(tumor) prosthesis | 0 (0) | 5 (2.4) | |
| Amputation | 0 (0) | 2 (1.0) | |
| Adjuvant therapy, n (%) | 5 (7) | 53 (25.2) | |
| Radiotherapy | 4 (6) | 18 (8.6) | |
| 90-Yttrium | 1 (1) | 14 (6.7) | |
| Systemic | 0 (0) | 15 (7.1) | |
| Otherb | 0 (0) | 6 (2.9) | |
| Recurrent disease, n (%) | 24 (36) | 146 (69.5) | |
| Additional surgery, n (%) | 23 (34) | 125 (59.5) | |
| Arthroscopic synovectomy | 7 (10) | 32 (15.2) | |
| Open synovectomy (one- or two-staged) | 10 (15) | 74 (35.2) | |
| Combined arthroscopic/open synovectomy | 1 (1) | 4 (1.9) | |
| Total joint replacement/(tumor) prosthesis | 2 (3) | 12 (5.7) | |
| Amputation | 3 (4) | 3 (1.4) | |
aTGCT: tenosynovial giant cell tumor.
bOther adjuvant therapies were cryosurgery, burning tools, steroid injections, or combination of multiple adjuvant therapies.